Skip to main content
CTSO logo

CTSO · Cytosorbents Corp

Track CTSO — free
$0.40 +0.04 (+10.38%) At close · Aug 14
Market Cap
$25.13M
Shares
62.84M

Cytosorbents Corp Earnings Call Transcripts

Every quarterly earnings call for Cytosorbents Corp (CTSO) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Earnings call
FY26 · Q2
2026-08-06
Cytosorbents Corp Q2 FY2026 Earnings Call
Revenue
$9.63M
▲ 0.2% YoY
Diluted EPS
$-0.07
▼ 333.3% YoY
Gross margin
73.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-13
Cytosorbents Corp Q1 FY2026 Earnings Call
Positive tone DrugSorb-ATR U.S. regulatory pathway Core CytoSorb international commercial performance Geopolitical disruption in the Middle East
Revenue
$8.86M
▲ 1.6% YoY
Diluted EPS
$-0.08
Gross margin
69.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-25
Cytosorbents Corp Q4 FY2025 Earnings Call
Positive tone DrugSorb-ATR FDA resubmission Germany restructuring and sales recovery Path to operating cash flow break-even
Revenue
$9.23M*
▲ 0.9% YoY
Gross margin
73.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-13
Cytosorbents Corp Q3 FY2025 Earnings Call
Positive tone DrugSorb-ATR FDA Pathway Germany Sales Restructuring Cash Flow Breakeven Path
Revenue
$9.48M
▲ 10.1% YoY
Diluted EPS
$-0.05
Gross margin
70.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Cytosorbents Corp Q2 FY2025 Earnings Call
Positive tone CytoSorb product and sepsis clinical evidence DrugSorb ATR regulatory process Gross margin performance
Revenue
$9.62M
▲ 8.8% YoY
Diluted EPS
$0.03
Gross margin
70.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
Cytosorbents Corp Q1 FY2025 Earnings Call
Positive tone DrugSorb-ATR regulatory status Core CytoSorb business performance Germany sales reorganization
Revenue
$8.73M
▼ 2.9% YoY
Diluted EPS
$-0.02
Gross margin
71.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-04
Cytosorbents Corp Q4 FY2024 Earnings Call
Revenue
$9.15M*
▲ 5.6% YoY
Gross margin
68.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-01
Cytosorbents Corp Q3 FY2024 Earnings Call
Positive tone DrugSorb ATR U.S. and Canada regulatory pathway CytoSorb international core business growth PuriFi pump as enabling technology
Revenue
$8.61M
▼ 2.2% YoY
Diluted EPS
$-0.05
Gross margin
61.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Cytosorbents Corp Q2 FY2024 Earnings Call
Positive tone DrugSorb-ATR Regulatory Submission Revenue and Product Sales Growth Taiwan Market Opportunity
Revenue
$8.84M
▼ 6.1% YoY
Diluted EPS
$-0.08
Gross margin
73.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Cytosorbents Corp Q1 FY2024 Earnings Call
Positive tone DrugSorb-ATR regulatory submissions Clinical evidence and new indications Product sales growth and post-COVID recovery
Revenue
$8.99M
▼ 4.9% YoY
Diluted EPS
$-0.11
Gross margin
76.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-15
Cytosorbents Corp Q4 FY2023 Earnings Call
Balanced tone STAR-T trial and regulatory pathway for DrugSorb-ATR India distribution partnership with Eris Lifesciences/ARRIS Sales performance and growth across regions
Revenue
$8.67M
▼ 7.7% YoY
Diluted EPS
$-0.12
Gross margin
61.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Cytosorbents Corp Q3 FY2023 Earnings Call
Revenue
$8.81M
▲ 8.6% YoY
Diluted EPS
$-0.21
Gross margin
63.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Cytosorbents Corp Q2 FY2023 Earnings Call
Revenue
$9.42M
▲ 10.9% YoY
Diluted EPS
$-0.15
Gross margin
63.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Cytosorbents Corp Q1 FY2023 Earnings Call
Revenue
$9.45M
▲ 8.7% YoY
Diluted EPS
$-0.17
Gross margin
57.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-09
Cytosorbents Corp Q4 FY2022 Earnings Call
Revenue
$9.39M
▼ 12.9% YoY
Diluted EPS
$-0.02
Gross margin
61.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Cytosorbents Corp Q3 FY2022 Earnings Call
Revenue
$8.11M
▼ 16.9% YoY
Diluted EPS
$-0.28
Gross margin
44.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Cytosorbents Corp Q2 FY2022 Earnings Call
Revenue
$8.50M
▼ 29.3% YoY
Diluted EPS
$-0.25
Gross margin
58.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Cytosorbents Corp Q1 FY2022 Earnings Call
Revenue
$8.69M
▼ 18% YoY
Diluted EPS
$-0.21
Gross margin
73.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-08
Cytosorbents Corp Q4 FY2021 Earnings Call
Revenue
$10.78M
▼ 9.8% YoY
Diluted EPS
$-0.25
Gross margin
71.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-10-13
Cytosorbents Corp Q3 FY2021 Earnings Call
Revenue
$9.76M
▼ 7.5% YoY
Diluted EPS
$-0.15
Gross margin
74.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Cytosorbents Corp Q2 FY2021 Earnings Call
Revenue
$12.02M
▲ 22.8% YoY
Diluted EPS
$-0.11
Gross margin
77.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Cytosorbents Corp Q1 FY2021 Earnings Call
Revenue
$10.60M
▲ 21.7% YoY
Diluted EPS
$-0.10
Gross margin
74.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-09
Cytosorbents Corp Q4 FY2020 Earnings Call
Revenue
$11.96M
▲ 60.9% YoY
Diluted EPS
$0.00
Gross margin
78.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Cytosorbents Corp Q3 FY2020 Earnings Call
Revenue
$10.55M
▲ 73% YoY
Diluted EPS
$-0.02
Gross margin
72.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Cytosorbents Corp Q2 FY2020 Earnings Call
Revenue
$9.79M
▲ 57.2% YoY
Diluted EPS
$-0.08
Gross margin
66.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Cytosorbents Corp Q1 FY2020 Earnings Call
Revenue
$8.71M
▲ 67.7% YoY
Diluted EPS
$-0.10
Gross margin
72.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-05
Cytosorbents Corp Q4 FY2019 Earnings Call
Revenue
$7.43M
▲ 22.2% YoY
Diluted EPS
$-0.13
Gross margin
71.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–27 of 27 earnings calls
Key facts CIK 1175151 CUSIP 23283X206 13F (30d) 50 filings 50 filers Visit website Investor relations